- Home
- TPST vs FGEN Comparison
TPST vs FGEN Comparison
Compare TPST & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TPST
- FGEN
- Stock Information
- Founded
- TPST 2011
- FGEN 1993
- Country
- TPST United States
- FGEN United States
- Employees
- TPST N/A
- FGEN N/A
- Industry
- TPST Biotechnology: Pharmaceutical Preparations
- FGEN Biotechnology: Pharmaceutical Preparations
- Sector
- TPST Health Care
- FGEN Health Care
- Exchange
- TPST Nasdaq
- FGEN Nasdaq
- Market Cap
- TPST 33.0M
- FGEN 33.5M
- IPO Year
- TPST N/A
- FGEN 2014
- Fundamental
- Price
- TPST $7.76
- FGEN $7.45
- Analyst Decision
- TPST Hold
- FGEN Strong Buy
- Analyst Count
- TPST 3
- FGEN 1
- Target Price
- TPST $30.00
- FGEN $250.00
- AVG Volume (30 Days)
- TPST 80.4K
- FGEN 48.5K
- Earning Date
- TPST 08-07-2025
- FGEN 08-05-2025
- Dividend Yield
- TPST N/A
- FGEN N/A
- EPS Growth
- TPST N/A
- FGEN N/A
- EPS
- TPST N/A
- FGEN N/A
- Revenue
- TPST N/A
- FGEN $6,996,000.00
- Revenue This Year
- TPST N/A
- FGEN N/A
- Revenue Next Year
- TPST N/A
- FGEN N/A
- P/E Ratio
- TPST N/A
- FGEN N/A
- Revenue Growth
- TPST N/A
- FGEN N/A
- 52 Week Low
- TPST $5.35
- FGEN $4.50
- 52 Week High
- TPST $28.34
- FGEN $33.49
- Technical
- Relative Strength Index (RSI)
- TPST 63.65
- FGEN 55.79
- Support Level
- TPST $6.11
- FGEN $7.31
- Resistance Level
- TPST $6.49
- FGEN $7.82
- Average True Range (ATR)
- TPST 0.35
- FGEN 0.59
- MACD
- TPST 0.03
- FGEN 0.10
- Stochastic Oscillator
- TPST 100.00
- FGEN 69.35
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.